Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participantsJOURNAL OF HEPATOLOGYIF332018-04-011PREAI
Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876CHEMMEDCHEMIF3.42017-07-2513PREAI
Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor ElbasvirANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52015-11-0161OAAI
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III studyJOURNAL OF GASTROENTEROLOGYIF5.52015-09-2517OAAI
P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325CHEMMEDCHEMIF3.42015-03-1021PREAI
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 InfectionCLINICAL INFECTIOUS DISEASESIF7.32014-09-2839OAAI
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants (vol 56, pg 4161, 2012)ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52014-08-012OAAI
COMPARATIVE RESISTANCE ANALYSIS BETWEEN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT EXPERIENCED PATIENTS WHO FAILED TREATMENT WITH A COMBINATION OF VANIPREVIR (MK-7009) AND PEGYLATED INTERFERON AND RIBAVIRIN (P/R)JOURNAL OF HEPATOLOGYIF332014-04-010PREAI
Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype ActivityCHEMMEDCHEMIF3.42013-10-14188OA
MK-5172 IN COMBINATION WITH PEG-INTERFERON/RIBAVIRIN DEMONSTRATES ROBUST EFFICACY AND A LOW RATE OF RESISTANCE-ASSOCIATED VIROLOGIC FAILURE IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HCV-INFECTED PATIENTSJOURNAL OF HEPATOLOGYIF332013-04-011PREAI
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant VariantsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52012-08-01210OA
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42012-03-02160OA
RIBAVIRIN NEITHER ENHANCES NOR ANTAGONIZES THE IN VIVO ACTIVITY OF VANIPREVIR IN THE CHIMPANZEE MODEL OF CHRONIC HCV INFECTIONJOURNAL OF HEPATOLOGYIF332011-03-010PREAI
Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral AgentsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52011-02-0144OAAI
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureACS MEDICINAL CHEMISTRY LETTERSIF42011-01-1237OAAI
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorJOURNAL OF MEDICINAL CHEMISTRYIF6.82010-02-17157PREAI
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52010-01-01127OAAI
Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected ChimpanzeesANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52009-03-01111OAAI
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assayANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52005-05-01115OAAI
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92003-12-01341OAAI